Pfizer sees strong prospects based on rapid integration of Pharmacia and expanded product and R&D opportunities
Pfizer sees strong prospects based on rapid integration of Pharmacia and expanded product and R&D opportunities Pfizer Estimates 16 Percent Compounded Annual Growth in Adjusted Diluted EPS* Between 2002-2004; Pharmacia Acquisition To Add $.06 to Diluted EPS In 2004 Significant Progress Made Toward Goal Of Filing 20 Medicines By 2006; Late-Stage Pipeline Includes Major Products In CNS Disorders, Pain, HIV/AIDS, Cardiovascular Disease And Smoking Cessation; $7.1 Billion R&D Investment In 2003 Leads Industry Pfizer Leads Worldwide Pharmaceutical Industry With 33 Major Products In 10